Posted by Diabetes South Texas Staff
News
Saturday, July 5th, 2014
ADA: San Francisco, California June 17, 2014
Studies show more sprawl associated with higher incidence of poor health outcomes
People who live in neighborhoods that are conducive to walking experienced a substantially lower rate of obesity, overweight and diabetes than those who lived in more auto-dependent neighborhoods, according to a pair of studies presented at the American Diabetes Association’s 74th Scientific Sessions®.
Researchers in Canada compared adults living in the most and least “walkable” metropolitan areas in southern Ontario and found a lower risk of developing diabetes over a 10-year period for those who lived in neighborhoods with less sprawl, more interconnectivity among streets, and more local stores and services within walking distance, among other measures used to determine a neighborhood’s “walkability.” The researchers controlled for variables, such as health at baseline, in order to rule out the probability that healthier people were choosing more walkable neighborhoods to begin with. A second study that compared neighborhoods, not individuals, found that the most walkable neighborhoods had the lowest incidence of obesity, overweight and diabetes. Read More
Posted by Diabetes South Texas Staff
News
Saturday, July 5th, 2014
Future Medicine: May 2014
As diabetes is a common disease state that is often underdiagnosed and undermanaged, this article aims to provide a practical approach to understanding the details of widely accepted recommendations for diabetes in the USA. Three guidelines are reviewed highlighting screening, diagnosis and treatment algorithms, with a focus on practical application to a patient scenario. The guidelines reviewed are published by the American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD), the American Association of Clinical Endocrinologists (AACE) and the American College of Physicians (ACP). By applying to the scenario of a newly diagnosed diabetic patient, this article aspires to highlight treatment differences between each expert recommendation, providing insight into evaluations made to determine the ideal initial treatment regimen. Read More
Posted by Diabetes South Texas Staff
Minority Diabetes Reports
Monday, May 5th, 2014
Diabetes Care: April 10, 2014
OBJECTIVE To compare a peer leader (PL) versus a community health worker (CHW) telephone outreach intervention in sustaining improvements in HbA1cover 12 months after a 6-month diabetes self-management education (DSME) program.
RESEARCH DESIGN AND METHODS One hundred and sixteen Latino adults with type 2 diabetes were recruited from a federally qualified health center and randomized to 1) a 6-month DSME program followed by 12 months of weekly group sessions delivered by PLs with telephone outreach to those unable to attend or 2) a 6-month DSME program followed by 12 months of monthly telephone outreach delivered by CHWs. The primary outcome was HbA1c. Secondary outcomes were cardiovascular disease risk factors, diabetes distress, and diabetes social support. Assessments were conducted at baseline, 6, 12, and 18 months. Read More
Posted by Diabetes South Texas Staff
Clinical Trial News
Monday, May 5th, 2014
Diabetologia/Springer Link: May 2014
Aims/hypothesis
The cholesterol absorption inhibitor ezetimibe has been shown to ameliorate non-alcoholic fatty liver disease (NAFLD) pathology in a single-armed clinical study and in experimental animal models. In this study, we investigated the efficacy of ezetimibe on NAFLD pathology in an open-label randomised controlled clinical trial.
Methods
We had planned to enrol 80 patients in the trial, as we had estimated that, with this sample size, the study would have 90% power. The study intervention and enrolment were discontinued because of the higher proportion of adverse events (significant elevation in HbA1c) in the ezetimibe group than in the control group. Thirty-two patients with NAFLD were enrolled and randomised (allocation by computer program). Ezetimibe (10 mg/day) was given to 17 patients with NAFLD for 6 months. The primary endpoint was change in serum aminotransferase level. Read More
Posted by Diabetes South Texas Staff
Clinical Trial News
Monday, May 5th, 2014
Diabetes Care: April 10, 2014
OBJECTIVE To assess the long-term effects of dietary interventions on glycemic control, need for diabetes medications, and remission of type 2 diabetes.
RESEARCH DESIGN AND METHODS Originally, in a two-arm trial design, overweight, middle-aged men and women with newly diagnosed type 2 diabetes were randomized to a low-carbohydrate Mediterranean diet (LCMD; n = 108) or a low-fat diet (n = 107). After 4 years, participants who were still free of diabetes medications were further followed up until the primary end point (need of a diabetic drug); remission of diabetes (partial or complete); and changes in weight, glycemic control, and cardiovascular risk factors were also evaluated. Read More
Posted by Diabetes South Texas Staff
Clinical Trial News
Monday, May 5th, 2014
Diabetes Care: April 10, 2014
OBJECTIVE To investigate the efficacy and tolerability of empagliflozin as an add-on to metformin therapy in patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS Patients with HbA1c levels of ≥7% to ≤ 10% (≥53 to ≤86 mmol/mol) while receiving metformin (≥1,500 mg/day) were randomized and treated with once-daily treatment with empagliflozin 10 mg (n = 217), empagliflozin 25 mg (n = 213), or placebo (n = 207) for 24 weeks. The primary end point was the change in HbA1c level from baseline at week 24. Key secondary end points were changes from baseline in weight and mean daily glucose (MDG) at week 24. Read More
Posted by Diabetes South Texas Staff
Clinical Trial News
Monday, May 5th, 2014
Diabetes Care: April 10, 2014
OBJECTIVE This 12-week study assessed the efficacy and tolerability of imeglimin as add-on therapy to the dipeptidyl peptidase-4 inhibitor sitagliptin in patients with type 2 diabetes that was inadequately controlled with sitagliptin monotherapy.
RESEARCH DESIGN AND METHODS In a multicenter, randomized, double-blind, placebo-controlled, parallel-group study, imeglimin (1,500 mg b.i.d.) or placebo was added to sitagliptin (100 mg q.d.) over 12 weeks in 170 patients with type 2 diabetes (mean age 56.8 years; BMI 32.2 kg/m2) that was inadequately controlled with sitagliptin alone (A1C ≥7.5%) during a 12-week run-in period. The primary efficacy end point was the change in A1C from baseline versus placebo; secondary end points included corresponding changes in fasting plasma glucose (FPG) levels, stratification by baseline A1C, and percentage of A1C responders. Read more
